How Long Does Xanax Stay in Your System: Full Timeline

After a single therapeutic dose, Xanax (alprazolam) is mostly cleared from the bloodstream within two to four days, but traces can linger in urine for roughly a day and a half and in hair for months. The timeline varies more than people expect, because factors like body composition, liver health, and other medications can double or even triple the time it takes your body to break the drug down. The detection window also depends heavily on what kind of test is being used and, perhaps surprisingly, on whether the test is even designed to pick up Xanax in the first place.

How Quickly Xanax Reaches Peak Levels

Xanax is absorbed efficiently. More than 90% of an oral dose makes it into your bloodstream, and peak blood levels are typically reached within about one to two hours after swallowing a tablet.¹ Some studies put the peak slightly earlier, around 0.7 to 1.6 hours.² That fast absorption is part of why Xanax works so quickly for acute anxiety or panic attacks, and it also means the drug starts being broken down almost as soon as it peaks. The noticeable calming effect of a dose fades well before the drug fully leaves your body, which is an important distinction when thinking about detection timelines.

The Elimination Half-Life

The half-life of a drug is the time it takes for the concentration in your blood to drop by half. For Xanax, the half-life in healthy adults has been measured at around 11 to 12 hours in controlled studies, though at steady state (when you’ve been taking it regularly) the half-life extends to roughly 19 hours.² That range matters. A drug is generally considered cleared after about five half-lives, which means a single dose taken by a healthy person could be gone from the blood in two to three days, while someone taking it daily might need four or more days after their last dose before blood levels become negligible.

Xanax is broken down primarily by liver enzymes in the CYP3A family, mainly CYP3A4 and CYP3A5.³ These enzymes convert alprazolam into two main metabolites. One of them, alpha-hydroxyalprazolam, is itself pharmacologically active and is also the metabolite that drug tests target in urine.⁴ The other metabolite, 4-hydroxyalprazolam, is less active. Both are eventually processed further and excreted through the kidneys.

Detection Windows by Test Type

The answer to “how long does Xanax stay in your system” depends almost entirely on what specimen is being tested. Each type of test has a different window, and none of them perfectly match the timeline of blood clearance.

Urine

Urine testing is the most common method used for workplace and clinical drug screens. In a controlled study where healthy volunteers took a single therapeutic dose of alprazolam, the median detection time for the primary metabolite (alpha-hydroxyalprazolam) in urine was 36 hours, with a range of 26 to 61 hours.⁵ In an earlier study using a specialized gas chromatography method, researchers tracked alprazolam and its metabolites in urine over 48 hours after a single dose, finding that alpha-hydroxyalprazolam appeared at the highest concentrations and was the most reliably detectable marker.⁶ For someone taking Xanax daily at higher doses, the detection window in urine will be longer than these single-dose figures, potentially extending to several days or more.

Oral Fluid (Saliva)

Saliva testing is gaining popularity because it is easy to collect and harder to tamper with. After a single therapeutic dose, the median detection time for alprazolam in oral fluid was 26 hours, ranging from 4 to 37 hours across individuals.⁵ In patients admitted to detoxification programs who had been taking high and repeated doses, the maximum detection time for alprazolam in oral fluid stretched to 2.5 days.⁷ That gap between the single-dose and chronic-use windows illustrates how much dosing history matters.

Blood

Blood tests are the most direct measure of current drug levels but have the shortest practical detection window. Because Xanax has a half-life in the range of 11 to 19 hours, blood concentrations drop below detectable thresholds within roughly one to three days after the last dose, depending on individual metabolism and how long the person was taking it. Blood testing is most useful in emergency departments and forensic settings where the question is whether someone is currently under the influence, not whether they used a drug last week.

Hair

Hair testing has the longest detection window of any method. Drugs are incorporated into the hair shaft as it grows, and because the chemical stays locked in the strand, hair can reveal drug use over a period of months. The standard approach analyzes a section of hair representing about 90 days of growth. A forensic review noted that hair offers a longer detection window than urine or blood because drugs remain stable in the shaft over time.⁸ The main limitation is that a single low dose may not deposit enough drug into the hair to be detected, so hair testing is more reliable for confirming repeated or sustained use.

Why Standard Drug Screens Often Miss Xanax

This catches many people off guard. The most widely used workplace and clinical drug screens rely on immunoassay technology, which uses antibodies designed to react to benzodiazepine metabolites. The problem is that these antibodies were originally calibrated for older benzodiazepines like diazepam and its metabolites, and they do not cross-react well with alprazolam or its breakdown products. The standard immunoassay cutoff is typically in the range of 200 to 300 ng/mL.⁹ ¹⁰

Alprazolam and its metabolites tend to produce weak signals on these assays, meaning that even when someone has recently taken Xanax, the test can come back negative. One laboratory study found that lowering the trigger threshold on the immunoassay substantially improved the detection rate, and that reflexing to a more sensitive confirmation technique (liquid chromatography with mass spectrometry) was necessary to catch many positive cases.¹⁰ If you are being specifically tested for alprazolam, the lab needs to either use a targeted assay or confirm with mass spectrometry. A generic “benzo” screen can easily miss it.

Factors That Change How Long Xanax Stays in Your Body

The half-life figures cited earlier come from studies of relatively healthy adults. In practice, several factors can stretch the clearance timeline considerably.

Liver Function

Because Xanax is metabolized almost entirely in the liver, anything that impairs liver function slows its breakdown. In a study comparing patients with alcoholic liver disease to healthy controls, the half-life nearly doubled, going from about 11.4 hours in healthy subjects to 19.7 hours in those with liver disease. Clearance dropped from 1.2 to 0.6 mL/min/kg.¹¹ The practical implication is that someone with a compromised liver could take twice as long to clear the same dose, and the drug accumulates more with repeated dosing.

Body Composition

Obesity has a striking effect on how long Xanax lingers. In a pharmacokinetic study comparing obese subjects to normal-weight controls, the half-life of alprazolam doubled, averaging 22 hours in the obese group versus 11 hours in controls. The mechanism was not slower metabolism but a larger volume of distribution: the drug spread into a larger mass of tissue (mean 114 liters vs. 73 liters), which slowed the rate at which it could be cleared.¹² The researchers noted that during long-term use, obese patients take longer to reach stable blood levels and longer to clear the drug once they stop, though the final steady-state concentrations should be similar if dosing is based on ideal body weight rather than total body weight.

Drug Interactions

Anything that inhibits or speeds up the CYP3A4 enzyme system will change Xanax’s half-life. The most dramatic example in the literature involves erythromycin, a common antibiotic that inhibits CYP3A4. When healthy volunteers took alprazolam with erythromycin, the half-life more than doubled, jumping from about 16 hours to roughly 40 hours, and oral clearance fell by more than half.¹³ Antifungal drugs like ketoconazole and itraconazole are even more potent CYP3A4 inhibitors and would be expected to produce a similar or larger effect.¹⁴

On the other side, drugs that speed up CYP3A4 activity can clear Xanax faster than expected. Rifampin (an antibiotic used for tuberculosis), carbamazepine (a seizure medication), and phenytoin (another anti-seizure drug) are all potent enzyme inducers that can reduce Xanax blood levels enough to undermine its therapeutic effect.¹⁴ Grapefruit juice is a weaker but more commonly encountered CYP3A4 inhibitor and can modestly slow Xanax clearance as well.

Age

Older adults tend to metabolize benzodiazepines more slowly, partly because liver enzyme activity declines with age and partly because body composition changes. While the pharmacokinetic study of the extended-release formulation found that adolescents and adults in the 20-to-45 age range had fairly similar drug exposure after a single dose,¹⁵ the picture changes in adults over 65, who typically have higher peak levels and longer clearance times. Prescribing guidelines generally recommend lower doses for elderly patients for this reason.

Extended-Release Xanax (Xanax XR)

Xanax XR is designed to release alprazolam more gradually, producing a flatter blood-level curve throughout the day rather than a sharp peak and trough. The total amount of drug absorbed is essentially the same as with the immediate-release version, but the peak concentration is lower and reached later. In a study comparing adolescents (ages 13 to 17) and adults (ages 20 to 45) given single doses of Xanax XR at 1 mg and 3 mg, the overall drug exposure was similar between the two age groups, and the 3 mg dose produced roughly proportional increases in blood levels compared to the 1 mg dose.¹⁵ For detection purposes, the XR formulation does not dramatically change how long the drug stays in your system after your last dose, but because it is often prescribed at higher total daily doses for sustained-release effect, someone taking XR may have more drug on board at any given time than someone on low-dose immediate-release Xanax.

When Effects Wear Off Versus When the Drug Is Gone

One of the most common sources of confusion is the gap between when Xanax stops working and when it leaves the body. The anxiolytic effect of a standard dose typically fades within four to six hours, which is why immediate-release Xanax is often prescribed two or three times a day. But the drug and its active metabolites persist in your blood and tissues long after you stop feeling anything. This mismatch can create problems in both directions. People sometimes take another dose too soon because the calming effect has worn off, not realizing their body hasn’t finished processing the previous one. And people sometimes assume they are “clean” a day or two after their last dose because they feel normal, when the drug and its metabolites are still present and detectable.

Withdrawal Is Not the Same as Clearance

The timeline for clearing Xanax from your body is separate from the timeline for withdrawal symptoms, and the two should not be confused. Withdrawal can start as the blood level drops below what your brain has adapted to, which for regular Xanax users can be within 6 to 12 hours of a missed dose. Symptoms typically peak at one to four days and can include rebound anxiety, insomnia, tremors, and in severe cases, seizures. A fatal case report described a woman who had been taking extremely high doses (roughly 200 mg over six days) and abruptly stopped. She developed seizure-like activity and died within hours of hospital admission, about four days after her last dose.¹⁶ That case involved extraordinary doses far beyond normal prescribing, but it illustrates why abrupt discontinuation after regular use is dangerous and why tapering under medical supervision is the standard of care.

The withdrawal timeline also does not neatly track drug clearance. Protracted withdrawal symptoms, including heightened anxiety, insomnia, and sensory disturbances, can persist for weeks or even months after the drug is fully out of the body. This happens because the brain’s own calming mechanisms have been suppressed during chronic use and need time to recalibrate. Someone going through protracted withdrawal has no detectable Xanax in any specimen, but they can feel as bad as or worse than when they started the medication.

Xanax and Breastfeeding

A concern that comes up frequently is whether Xanax passes into breast milk and, if so, for how long. Like most benzodiazepines, alprazolam does transfer into milk, but the concentrations are low. A study measuring benzodiazepine levels in breast milk and plasma found that for alprazolam and related drugs, the milk-to-plasma ratios remained below 1 (meaning the drug was less concentrated in milk than in blood), and the estimated relative infant dose was below 10%, a threshold generally considered compatible with breastfeeding.¹⁷ No abnormalities were found in the breastfeeding infants in that study. Still, because Xanax has sedative effects and neonates metabolize drugs more slowly, the decision to use it while nursing should involve a conversation with a prescriber about both the dose and the infant’s age and health.

Postmortem and Forensic Considerations

In forensic toxicology, the question of how long Xanax “stays” takes on a different meaning. After death, drugs can redistribute from organs with high concentrations (like the liver) back into the blood, making postmortem blood levels unreliable as estimates of what the person had in their system while alive. Studies of alprazolam’s postmortem redistribution have found that cardiac blood concentrations can increase roughly twofold compared to levels at the time of death.¹⁸ The ratio of cardiac to peripheral blood concentration for alprazolam has been measured at about 1.22, indicating moderate redistribution.¹⁹ For medical examiners, this means that an alprazolam level in postmortem blood cannot simply be compared to therapeutic ranges established in living patients. Peripheral blood (drawn from the femoral vein, for example) gives a more accurate picture than cardiac blood, but even peripheral samples are interpreted cautiously.

The highest tissue concentrations in animal studies were found in fat and liver, while brain and lung levels were lower.¹⁸ The fat-storage finding echoes the pharmacokinetic data in living subjects showing that a larger volume of distribution (as seen in obese individuals) slows clearance. In both living and forensic contexts, Xanax’s affinity for fatty tissue extends the time it can be found in the body beyond what the blood half-life alone would predict.

1
PubMed. The pharmacology of alprazolam: a review
2
PubMed. Alprazolam (Xanax, the Upjohn Company)
3
PubMed. In vitro/in vivo scaling of alprazolam metabolism by CYP3A4 and CYP3A5 in humans
4
PubMed. Differential metabolism of alprazolam by liver and brain cytochrome (P4503A) to pharmacologically active metabolite
5
PubMed. An Experimental Study of Diazepam and Alprazolam Kinetics in Urine and Oral Fluid Following Single Oral Doses
6
PubMed. Detection of alprazolam (Xanax) and its metabolites in urine using dual capillary column, dual nitrogen detector gas chromatography
7
Therapeutic Drug Monitoring. Detection Times of Diazepam, Clonazepam, and Alprazolam in Oral Fluid Collected From Patients Admitted to Detoxification, After High and Repeated Drug Intake
8
PubMed Central. Hair testing for investigating intake and use history of hypnotics in the forensic field
9
PubMed. Measurement of benzodiazepines in urine by liquid chromatography-tandem mass spectrometry: confirmation of samples screened by immunoassay
10
The Journal of Applied Laboratory Medicine. Improved Clinical Sensitivity of a Reflexive Algorithm to Minimize False-Negative Test Results by a Urine Benzodiazepine Immunoassay Screen
11
PubMed. Alprazolam pharmacokinetics in alcoholic liver disease
12
PubMed. The influence of obesity on the pharmacokinetics of oral alprazolam and triazolam
13
PubMed. A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in alprazolam metabolism
14
The Journal of Clinical Pharmacology. Pharmacokinetic and Pharmacodynamic Consequences of Metabolism‐Based Drug Interactions with Alprazolam, Midazolam, and Triazolam
15
American Journal of Therapeutics. Pharmacokinetics of an Extended Release Formulation of Alprazolam (Xanax XR) in Healthy Normal Adolescent and Adult Volunteers
16
The American Journal of Forensic Medicine and Pathology. A Fatal Case of Benzodiazepine Withdrawal
17
PubMed Central. Benzodiazepine Concentrations in the Breast Milk and Plasma of Nursing Mothers: Estimation of Relative Infant Dose
18
Journal of Forensic Toxicology & Pharmacology. Review of Alprazolam in Forensic Toxicology
19
Toxicologie Analytique et Clinique. Postmortem redistribution of triazolam, alprazolam, delorazepam (chlordesmethyldiazepam) and zolpidem in a suicide case